The Company reiterates anticipated full year 2023 net product revenues from JELMYTO to be in the range of $76 to $86M. The Company also reiterates anticipated full year 2023 operating expenses in the range of $135 to $145M, including non-cash share-based compensation expense of $6.0 to $11.0M, subject to market conditions. The Company also reiterates anticipated full year 2023 non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $21.0 to $26M. Of this amount approximately $9.9 to $11.2M is expected to be in cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on URGN:
- URGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ‘Opportunities Outweigh Risks’: Oppenheimer Sees at Least 60% Gains in These 2 Stocks
- UroGen Pharma price target raised to $54 from $23 at H.C. Wainwright
- UroGen Pharma price target raised to $52 from $47 at Ladenburg
- UroGen Pharma price target raised to $33 from $22 at Oppenheimer
